Clinical trials: Glaucoma Therapy
Open Angle Glaucoma, Ocular Hypertension
Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT
The objective of the study is to evaluate evaluate the safety and IOP lowering efficacy of OTX-TP, a sustained release travoprost drug product, placed in the canaliculus of the eyelid in the treatment of subjects with open-angle…
- Trial name
- NCT02914509
- Testing
- Travoprost
- Where
- 10 sites in United States
- Volunteers
- 565 people
- Sponsor
- Ocular Therapeutix, Inc.
Primary Open Angle Glaucoma and Cataracts
PEI-GT Trial for Initial Treatment of Primary Open-Angle Glaucoma With Cataract
The goal of this clinical trial is to learn whether doing phacoemulsification combined with gonioscopy-assisted trabeculotomy as an initial treatment can reduce the burden of glaucoma eye drops in adults with primary open-angle…
- Trial name
- NCT07700498
- Testing
- PEI combined with gonioscopy-assisted trabeculotomy, PEI combined with conventional topical IOP-lowering medications
- Where
- 5 sites in China
- Volunteers
- 106 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Open Angle Glaucoma
Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients
Glaucoma is an optic neuropathy in which the main risk factor is intraocular pressure (IOP). The search for other variables involved in glaucoma pathogenesis and progression has identified both systemic and ocular signs of…
- Trial name
- NCT02053298
- Testing
- Timolol & Dorzolamide
- Where
- Belgium
- Volunteers
- 30 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Glaucoma
This Study Examines Whether Personality Traits Influence the Frequency or Severity of Ocular Adverse Effects Reported by Patients Using Glaucoma Medications. The Findings May Identify Patients at Greater Risk of Intolerance and Support More Personalized Treatment and Counselling.
The goal of this observational study is to learn whether personality traits are related to eye side effects from glaucoma medications in adults who currently use or previously used these medications.
- Trial name
- Adverse Events (NCT07739784)
- Testing
- No Interventions
- Where
- Canada
- Volunteers
- 352 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Refractory Glaucoma
Real-world Evidence Study of XEN in Chinese Patients With Refractory Glaucoma
Real-world evidence study to assess the safety and effectiveness of XEN® Glaucoma Treatment System in Chinese patients with refractory glaucoma.
- Trial name
- NCT04303897
- Testing
- XEN Glaucoma Stent
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Allergan
Glaucoma, Open-Angle, Ocular Hypertension
A Study to Assess the Efficacy of 3 Months of Latanoprost Treatment in Reducing the Intraocular Pressure in Patients With Ocular Hypertension or Open-angle Glaucoma
The purpose of this study is to evaluate the effect of latanoprost on intraocular pressure reduction in patients with ocular hypertension or open-angle glaucoma.
- Trial name
- NCT00647101
- Testing
- Latanoprost
- Where
- 176 sites in France
- Volunteers
- 600 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Glaucoma, Glaucoma, Open Angle
SOLX Gold Shunt Versus Control Implant: Randomized Trial for Refractory Glaucoma
Study Objective: To establish the substantial equivalence of the SOLX Gold Shunt to commercially available aqueous shunts, specifically the Ahmed™ Glaucoma Valve Model FP7, in the ability to reduce intraocular pressure (IOP)…
- Trial name
- NCT00382395
- Testing
- SOLX Gold Shunt GMS-plus, Ahmed FP7 Glaucoma Valve
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 180 people
- Sponsor
- SOLX, Inc.
Open-angle Glaucoma, Ocular Hypertension
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
The purpose of the study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension
- Trial name
- NCT00293761
- Testing
- Travoprost, Investigational, Travoprost (TRAVATAN)
- Volunteers
- 109 people
- Sponsor
- Alcon Research
Glaucoma Open-Angle Primary, Cataract
Comparing the Effectiveness of Phacoemulsification + ECP Laser and Phacoemulsification Alone for Glaucoma Patients
Laser endoscopic cyclophotocoagulation (ECP) has been in use for the treatment of glaucoma for over 20 years and is usually used in conjunction with cataract surgery.
- Trial name
- CONCEPT (NCT04295122)
- Testing
- Phacoemulsification+ Endoscopic cyclophotocoagulation (ECP) laser
- Volunteers
- 160 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Primary Open Angle Glaucoma, Intraocular Pressure
Effects of Forskolin on Intraocular Pressure in Glaucomatous Patients Under Maximum Tolerated Medical Therapy
Elevated intraocular pressure is still the main risk factor for development and progression of glaucoma. Several drugs exist on the market that may decrease IOP in glaucomatous patients.
- Trial name
- NCT00864578
- Where
- Italy
- Sponsor
- Sooft Italia
Glaucoma
VividWhite Glaucoma Implant (VW-51) Pivotal Study
The VividWhite Glaucoma Implant (VW-51) is a novel surgical implant designed to treat glaucoma. This study is a 12-month, 65-participant non-comparative multicentre study to assess the safety and effectiveness of the VW-51…
- Trial name
- NCT06176170
- Testing
- VividWhite Glaucoma Implant (VW-51)
- Where
- 6 sites in Australia
- Volunteers
- 65 people
- Sponsor
- VividWhite Pty Ltd
Macular Degeneration, Glaucoma
Deficits, Adaptation and Cerebral Functional Reorganization of Visual Retinotopic Treatments During Normal and Pathological Aging (Age-related Macular Degeneration and Glaucoma)
The main objective of this research is to study the cognitive and cerebral mechanisms of the integration of central and peripheral visual information during normal and pathological aging (ophthalmological patients with AMD and…
- Trial name
- VISIOPERICENT (NCT03133117)
- Testing
- Functional Magnetic Resonance Imaging (fMRI)
- Where
- France
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Corneal Epitheliopathy, Glaucoma
Efficacy of 20% Autologous Serum Drops in the Treatment of Corneal Epitheliopathy Associated With Antihypertensive Glaucoma Drops.
Introduction: Glaucoma is the second leading cause of blindness globally. Most anti-hypertensive drops contain preservatives harmful to the corneal epithelium, with up to 78% of treated patients reporting dry eye symptoms.
- Conditions
- Corneal Epitheliopathy, Glaucoma, Corneal Disease, Dry Eye
- Trial name
- NCT06294015
- Testing
- 20% ASED + AT, 0.9% NS + AT
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Université de Sherbrooke
Glaucoma, Intraocular Pressure
the Pops-titration Versus the Slow-coagulation Cyclophotocoagulation in Treatment of Refractory Glaucoma
Transcleral cyclophotocoagulation (TSCPC) has long been used as refractory glaucoma management and is very easy to learn and easy to perform.
- Trial name
- NCT01774227
- Testing
- The pops-titration group, The slow-coagulation group
- Where
- Thailand
- Volunteers
- 98 people
- Sponsor
- Prince of Songkla University
Open-Angle Glaucoma, Ocular Hypertension
Phase 3 Study to Evaluate IOP Lowering Therapy in Open Angle Glaucoma and Ocular Hypertension C-02-41
To compare intraocular pressure lowering effectiveness of a combination drug vs. two individual drugs dosed alone.
- Trial name
- NCT00047528
- Testing
- Alcon Investigational Agent
- Where
- United States
- Sponsor
- Alcon Research
Thyroid Eye Disease, Ocular Hypertension
The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.
The purpose of this study is to evaluate the potential secondary beneficial effect of prostaglandin analogues (PA) treatment in thyroid eye disease (TED) patients.
- Conditions
- Thyroid Eye Disease, Ocular Hypertension, Glaucoma
- Trial name
- NCT01927406
- Testing
- Prostaglandin Analog, Timolol
- Where
- United States
- Sponsor
- Stanford University
Primary Open Angle Glaucoma
RESEARCH PROTOCOL: Glaucoma Treatment Adherence and Persistence
The investigators are studying motivational interviewing (MI). MI is a counseling method to help people adopt healthy behaviors. The investigators will test whether MI improves patients' accurate use of glaucoma eye drops.
- Trial name
- NCT01409421
- Testing
- motivational interviewing, three phone calls to remind patients to take their eye drops
- Where
- 2 sites in United States
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Glaucoma
Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil
The purpose of this study was to assess the efficacy and tolerability of changing to AZARGA® from prior COMBIGAN® pharmacotherapy in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT01514734
- Testing
- Brinzolamide/timolol maleate fixed combination
- Where
- Brazil
- Volunteers
- 9 people
- Sponsor
- Alcon Research
Ophthalmopathy, Glaucoma
Phaco-Trabeculotomy Vs Phaco-Trabeculectomy
A prospective, randomized comparative study on adult patients with synechial angle closure glaucoma.
- Conditions
- Ophthalmopathy, Glaucoma, Glaucoma, Angle-Closure
- Trial name
- PDT vs PT (NCT04683055)
- Testing
- Phacoemulsification combined with trabeculectomy, Phacoemulsificaiton combined with ab-externo trabeculotomy
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Assiut University
Glaucoma
Intraocular Pressure (IOP) Lowering Efficacy of Transdermal Brimonidine Therapy
The purpose of this study is to evaluate the safety and effectiveness in lowering intraocular pressure (IOP) utilizing an experimental lotion containing 0.1% Brimonidine that is applied to the outside of one eyelid.
- Trial name
- NCT01345448
- Testing
- Brimonidine
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Nanduri, Padma, M.D., FACS